10.8
CiteScore
 
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
10.8
CiteScore
5.3
Impact Factor
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Corrigendum
Current Issue
Editorial
Erratum
Full Length Article
Full lenth article
Letter to Editor
Original Article
Research article
Retraction notice
Review
Review Article
SPECIAL ISSUE: ENVIRONMENTAL CHEMISTRY
View/Download PDF

Translate this page into:

Original Article
4 (
2
); 231-234
doi:
10.1016/j.arabjc.2010.06.042

Novel thiosemicarbazones derivatives bearing aromatic iodine moiety: Design, synthesis and anti-malarial activity

National Institute for Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai 200025, PR China

*Corresponding author. Tel.: +86 02164377008 zhanghaobing@hotmail.com (H.B. Zhang)

Disclaimer:
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.

Peer review under responsibility of King Saud University.

Available online 1 July 2010

Abstract

A series of thiosemicarbazones of aromatic iodide derivatives were designed and synthesized. The structures of all the newly synthesized compounds had been identified by elemental analysis, 1H NMR and 13C NMR. Their biological activities were evaluated against Plasmodium falciparum. Among these compounds, at concentrations of 3, 9 and 27 mg/kg of mouse per day, 4e inhibited the growth of the malaria parasite in vivo test in mice with the respective percentages: 88.1%, 90.7% and 92.6%. The present work suggest that thiosemicarbazones of aromatic iodide may become a lead compound for anti-malaria medicine.

Keywords

Anti-malarials
Thiosemicarbazone
Aromatic iodide
Plasmodium falciparum
1

1 Introduction

Malaria is one of the most significant infectious diseases in the world. It is endemic through the entire tropical region of the Earth, except for high mountain areas, deserts and a few islands (Cox-singh et al., 2008; Guinovart et al., 2006; Plowe, 2005; Newman et al., 2004; Leder et al., 2006). Chloroquine has been the most effective and widely used drug in malaria therapy. Therefore, great hopes have been placed on development of agents, which can reverse resistance to chloroquine (Uhlemann and Krishna, 2005; Nogueira et al., 2010). Recently there were a lot of studies using iron-chelating agents as a possible treatment for malaria (Cabantchik, 1994; Kontoghiorghes et al., 2010). Thiosemicarbazones are known iron-chelating agents by bonding through the sulfur and azomethine nitrogen atoms (Walcourt et al., 2004). Their activity against extracellular protozoan such as Plasmodium falciparum, Trichomonas vaginalis, Trypanosoma cruzi, and other parasites were demonstrated by several works (Greenbaum et al., 2004; Bharti et al., 2002).

On the other hand, iodine is a trace mineral required for human life. Iodine is important in the developing of the fetus, particularly in the brain. It helps the functioning of the heart, pancreas, liver, kidneys, muscles, and brain. Iodine promotes general growth and development of the body as well as metabolism of nutrients (Azuolas and Caple, 1984; Lamard and Tressol, 1989; Boyages, 1993). The replacement of chlorine atom by iodine atom led to compounds with a less toxicity and better biology activity. These prompted us to explore the biological activities of thiosemicarbazone analogs of aromatic iodide. In this context, we report the preparation of new thiosemicarbazones of aromatic iodide analog. These compounds were tested in vivo for their ability to inhibit the growth of malaria parasite.

2

2 Experimental

2.1

2.1 Material and reagents

All the reagents and solvents were of the commercial quality and were used without purification. Elemental analysis was performed on a PE-2400 elemental analyzer, the C, H and N analysis were repeated twice. 1H NMR and 13C NMR spectra were obtained with a Bruker AM-400 spectrometer with chemical shifts reported as ppm (in DMSO-d6, TMS as internal standard). Melting points were determined by an X-6 micro-melting point apparatus and were uncorrected.

2.2

2.2 General procedure for the preparation of 4-(p-iodophenyl)-3-thiosemicarbazone derivatives (4a4e)

The synthetic routes of the target compounds 4a4e were shown in Scheme 1. In a typical procedure (Hodgkins and Reeves, 1964). Aromatic iodine 1 (21.9 g, 0.1 mol) was dissolved in the minimum amount of benzene and treated with 7.0 mL of carbon disulfide and 16 mL of triethylamine in ice bath, then the solution filtered to get the solid, which was then dissolved in 90 mL of chloroform. A mixture of 15 mL of triethylamine and 10.2 mL of ethyl chlorocarbonate was added dropwise, followed by stirring for 1 h. The chloroform solution was washed with 3 mol L−1 HCl and water, respectively, and dried over sodium sulfate, then evaporated in vacuum to dryness to get crude solid, which on recrystallization with ethanol gave 2. Compound 2 (26.1 g, 0.1 mol) was dissolved in minimum amount of ethanol, and then was dropped to hydrazine hydrate (24 g, 0.4 mol) at ambient temperature. A white solid was separated, which was washed and dried to give 3. Equimolar quantities of thiosemicarbazones 3 and difference aldehydes were mixed in boiling ethanol for about 1–2 h, then solution was concentrated, the solid was filtered and recrystallized with ethanol and dried to give 4a4e.

The synthetic routes of the target compounds.
Scheme 1
The synthetic routes of the target compounds.

All the target compounds were pale yellow solid and stable at room temperature, insoluble in water and readily soluble in DMF and DMSO.

2.2.1

2.2.1 Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4a)

Yield 87%, m.p. 191–192 °C; 1H NMR (DMSO-d6, 400 MHz) δ: 11.71 (s, 1H, NH), 9.97 (s, 1H, NH), 9.91 (s, 1H, OH), 8.07 (s, 1H, CH⚌N), 7.73–6.80 (m, 8H, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ: 170.24, 140.18, 139.19, 134.62, 133.95, 126.41, 124.70, 113.63, 112.27, 109.28, 105.78, 103.44, 103.27, 90.29; Anal. calcd for C14H12IN3OS (397.2): C 42.33, H 3.04, N 10.58; found C 42.56, H 3.04, N 10.68.

2.2.2

2.2.2 Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4b)

Yield 90%, m.p. 202–203 °C; 1H NMR (DMSO-d6, 400 MHz) δ: 11.63 (s, 1H, NH), 9.91 (s, 1H, NH), 8.04 (s, 1H, CH⚌N), 7.68–6.73 (m, 8H, Ar-H), 2.97 (s, 6H, N(CH3)2); 13C NMR (DMSO-d6, 100 MHz) δ: 175.20, 149.21, 147.83, 142.89, 138.89, 137.77, 128.82, 126.18, 123.52, 123.49, 117.35, 112.30, 89.37, 40.94; Anal. calcd for C16H17IN4S (424.3): C 45.29, H 4.04, N 13.20; found C 45.34, H 4.14, N 13.18.

2.2.3

2.2.3 Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4c)

Yield 82%, m.p. 195–196 °C; 1H NMR (DMSO-d6, 400 MHz) δ: 11.73 (s, 1H, NH), 9.97 (s, 1H, NH), 9.51 (s, 1H, OH),8.06 (s, 1H, CH⚌N), 7.71–6.80 (m, 8H, Ar-H), 3.83 (s, 3H, OCH3); 13C NMR (DMSO-d6, 100 MHz) δ: 175.18, 149.10, 147.94, 143.88, 139.04, 136.66, 127.81, 125.16, 122.50, 122.48, 115.33, 110.29, 89.64, 55.83; Anal. calcd for C15H14IN3O2S (427.2): C 42.17, H 3.30, N 9.83; found C 42.10, H 3.37, N 9.96.

2.2.4

2.2.4 Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4d)

Yield 88%, m.p. 175–176 °C; 1H NMR (DMSO-d6, 400 MHz) δ: 11.63 (s, 1H, NH), 10.17 (s, 1H, NH), 9.94 (s, 1H, OH), 9.83 (s, 1H, OH), 8.36 (s, 1H, CH⚌N), 7.85–6.39 (m, 8H, Ar-H); 13C NMR (DMSO-d6, 100 MHz) δ: 168.04, 139.16, 137.09, 136.60, 132.90, 127.40, 125.69, 111.62, 110.26, 108.18, 107.75, 102.44, 102.24, 89.29; Anal. calcd for C14H12IN3O2S (413.2): C 40.69, H 2.93, N 10.17; found C 41.00, H 3.08, N 9.98.

2.2.5

2.2.5 Salicylaldehyde, 4-(p-iodophenyl)-3-thiosemicarbazone (4e)

Yield 85%, m.p. 201–202 °C; 1H NMR (DMSO-d6, 400 MHz) δ: 11.78 (s, 1H, NH), 10.07 (s, 1H, NH), 8.06 (s, 1H, CH⚌N), 7.81–6.94 (m, 7H, Ar-H); 6.08 (s, 2H, OCH2O); 13C NMR (DMSO-d6, 100 MHz) δ: 175.50, 149.09, 148.02, 138.98,138.81, 136.63, 135.14, 128.41, 128.03, 127.32, 124.36, 108.13, 105.58, 101.45, 89.80; Anal. calcd for C15H12IN3O2S (425.2): C 42.37, H 2.84, N 9.88; found C 42.13, H 2.74, N 9.91.

2.3

2.3 In vivo in mice anti-malarial study

The biology activities of the target compounds were evaluated against malaria parasite according with the standard test procedures (WHO standard).

3

3 Results and discussion

3.1

3.1 Synthesis of 4-(p-iodophenyl)-3-thiosemicarbazone derivatives and characterization

Firstly, aromatic iodine 1 was treated with carbon disulfide and chloroform to obtain isothiocyanate 2, and coupling reactions with hydrazine hydrate to give thiosemicarbazones 3. Then the title compounds 4a4e were successfully obtained using difference aldehydes as reagent. Compounds 4a4e were characterized by 1H NMR, 13C NMR and elemental analysis. All results are in full agreement with the proposed structures. For example, the singlet signal at 8.06 ppm (CH⚌N) and the signal at 6.08 ppm (OCH2O) of 1H NMR spectra suggest that compound 4e is consistent with its structure. The results of elemental analyses are in good agreement with those calculated for the suggested formula. The melting points are sharp indicating the purity of these compounds.

3.2

3.2 Anti-malarial activity

The biology activities of the target compounds were evaluated against malaria according to the standard bioactivity test procedures (WHO standard). The results were summarized in Table 1. From Table 1, we could find that these compounds showed significant anti-malarial activities in the four-day suppressive in vivo test in mice. At concentrations of 3, 9 and 27 mg/kg of mouse per day, in contrast, compound 4e produced the highest activity against malaria. For anti-malarial activity, structural variation between compounds 4a and 4b results in remarkably different activity. The only structural differences between 4a and 4b are the types of substituents at C-10. Compound 4a contain hydroxyl group moiety at C-10, while 4b has a N(CH3)2 group moiety at C-10. This hydroxyl group appears to be particularly responsible for anti-malarial activity. Compounds 4a, 4c and 4d, which contain hydroxyl group moiety at C-10, while 5 has 1,3-dioxolane ring on C-9/C-10 seemed to be much more effective in terms of anti-malarial activity. Furthermore, Compound 4e inhibited the growth of the malaria parasite with the respective percentages: 88.1%, 90.7% and 92.6%. The corresponding values for 5e at the same concentrations were 58.0%, 74.8% and 77.0%, respectively. It was worth noting that the thiosemicarbazones of aromatic iodide analog showed improved biology activities to some extent over aromatic chloride counterparts against malaria, which might be contributed by the introduction of iodine atom in benzene.

Table 1 The inhibition percentage of the target compounds against Plasmodium falciparum.
Compound Concentrations (mg/kg) Percentages of suppression of Plasmodium falciparum
4-(p-Iodophenyl)-3-thiosemicarbazone (4a) 3 60.2
9 78.2
27 80.0
4-(p-Iodophenyl)-3-thiosemicarbazone (4b) 3 54.3
9 60.2
27 65.3
4-(p-Iodophenyl)-3-thiosemicarbazone (4c) 3 62.3
9 79.1
27 80.2
4-(p-Iodophenyl)-3-thiosemicarbazone (4d) 3 64.3
9 80.4
27 82.1
4-(p-Iodophenyl)-3-thiosemicarbazone (4e) 3 88.1
9 90.7
27 92.6
4-(p-Chlorophenyl)-3-thiosemicarbazone (5e) 3 58.0
9 74.8
27 77.0

Chloroquine (3 mg/kg of mouse, positive control) had a suppressive activity of 100%.

4

4 Conclusions

In summary, various types of thiosemicarbazones of aromatic iodide were synthesized and their varying biology activities towards the malaria was demonstrated. The present work suggest that thiosemicarbazones of aromatic iodide may become a lead compound for anti-malaria medicine. Further structure–biology activity relationships about the designed compounds were under the way.

Acknowledgements

The authors wish to acknowledge that this project is supported by National Institute for Diseases (2010A102) and Shanghai Health Bureau.

References

  1. , , . Aust. Vet. J.. 1984;61:223.
  2. , , , , , , , . Bioorg. Med. Chem. Lett.. 2002;12:3475.
  3. , . J. Clin. Endocrinol. Metab.. 1993;77:587.
  4. , . Parasitol. Today. 1994;11:74.
  5. , , , . Clin. Infect. Dis.. 2008;46(2):165.
  6. , , , , , , , , , , . J. Med. Chem.. 2004;47:3212.
  7. , , , . Curr. Mol. Med.. 2006;6(2):137.
  8. , , . J. Org. Chem.. 1964;29:3098.
  9. , , , , , . Expert Opin. Drug Safe.. 2010;9(2):201.
  10. , , . Reprod. Nutr. Dev.. 1989;29:113.
  11. , , , . Clin. Infect. Dis.. 2006;43:1185.
  12. , , , . Ann. Intern. Med.. 2004;141(7):547.
  13. , , , , . Acta Trop.. 2010;114(2):109.
  14. , . Curr. Top. Microbiol. Immunol.. 2005;295:55.
  15. , , . Curr. Top. Microbiol. Immunol.. 2005;295:39.
  16. , , , , , . Int. J. Biochem. Cell Biol.. 2004;36:401.
Show Sections